Lyell Immunopharma (LYEL) Operating Expenses (2020 - 2026)

Lyell Immunopharma has reported Operating Expenses for 7 years, with the latest figure at $44.3 million in Q1 2026.

• Quarterly Operating Expenses fell 22.85% year-over-year to $44.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $256.3 million (down 28.92% YoY) and the FY2025 annual result came in at $269.4 million, down 24.91% from the prior year.
• Operating Expenses slipped to $44.3 million in Q1 2026 per LYEL's latest filing, from $127.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $201.2 million in Q4 2024 and troughed at $37.3 million in Q3 2025.
• A 5-year average of $70.1 million and a median of $59.5 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses soared 237.96% in 2024, then tumbled 36.54% in 2025.
• Over 5 years, Operating Expenses stood at $63.2 million in 2022, then decreased by 5.78% to $59.5 million in 2023, then jumped by 237.96% to $201.2 million in 2024, then sank by 36.54% to $127.6 million in 2025, then plunged by 65.32% to $44.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $44.3 million, $127.6 million, and $37.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.